Drugs / ARI-3037MO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02574325 | Oct 2015 → Oct 2016 | metabolic dysfunction-associated steatohepatitis | Arisaph Pharmaceuticals Inc | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT02532218 Comparator | Aug 2015 → Sep 2016 | hyperlipidemia | Arisaph Pharmaceuticals Inc | Unknown | No outcome recorded |
| Phase 2 | NCT02250105 Comparator | Sep 2014 → Jun 2016 | hypertriglyceridemia | Arisaph Pharmaceuticals Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARI-3037MO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02250105 ↗ |
| Route | Oral | “ARI-3037MO 3g bid orally for 12 weeks” NCT02250105 ↗ |